

LOVENBERG WALTER M PHD
 Form 3
 February 01, 2012

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *			2. Date of Event Requiring Statement		3. Issuer Name and Ticker or Trading Symbol	
Â LOVENBERG WALTER M PHD			(Month/Day/Year)		MERRIMACK PHARMACEUTICALS INC [MACK]	
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer			5. If Amendment, Date Original Filed(Month/Day/Year)
C/O MERRIMACK PHARMACEUTICALS, INC.,Â ONE KENDALL SQUARE, SUITE B7201			(Check all applicable)			
(Street)			<input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below)		6. Individual or Joint/Group Filing(Check Applicable Line)	
CAMBRIDGE,Â MAÂ 02139						<input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
(City)	(State)	(Zip)				

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	70,000	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date	3. Title and Amount of Securities Underlying	4. Conversion	5. Ownership	6. Nature of Indirect Beneficial
---	---	--	---------------	--------------	----------------------------------

Edgar Filing: LOVENBERG WALTER M PHD - Form 3

	(Month/Day/Year)		Derivative Security (Instr. 4)		or Exercise Price of Derivative Security	Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series D Convertible Preferred Stock	Â (1)	Â (1)	Common Stock	7,143	\$ (1)	D	Â
Stock Option (right to buy)	Â (2)	05/03/2012	Common Stock	5,462	\$ 2.19	D	Â
Stock Option (right to buy)	Â (2)	08/02/2012	Common Stock	20,000	\$ 2.19	D	Â
Stock Option (right to buy)	Â (2)	05/08/2013	Common Stock	15,000	\$ 2.19	D	Â
Stock Option (right to buy)	Â (2)	08/30/2014	Common Stock	25,000	\$ 1.25	D	Â
Stock Option (right to buy)	Â (2)	08/03/2015	Common Stock	20,000	\$ 1.71	D	Â
Stock Option (right to buy)	Â (2)	08/01/2016	Common Stock	20,000	\$ 2.47	D	Â
Stock Option (right to buy)	Â (2)	10/04/2017	Common Stock	20,000	\$ 2.59	D	Â
Stock Option (right to buy)	Â (2)	09/21/2018	Common Stock	20,000	\$ 1.81	D	Â
Stock Option (right to buy)	Â (2)	11/04/2019	Common Stock	20,000	\$ 2.12	D	Â
Stock Option (right to buy)	Â (2)	05/02/2021	Common Stock	53,000	\$ 5.54	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
LOVENBERG WALTER M PHD C/O MERRIMACK PHARMACEUTICALS, INC. ONE KENDALL SQUARE, SUITE B7201 CAMBRIDGE, MA 02139	Â X	Â	Â	Â

Signatures

/s/ Jeffrey A. Munsie,
attorney-in-fact

02/01/2012

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each share of Series D Convertible Preferred Stock will automatically convert into one share of Common Stock upon the closing of the issuer's initial public offering. The shares have no expiration date.
- (2) This option is fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.